Direkt zum Inhalt
Merck

Triptolide inhibits tumor growth by induction of cellular senescence.

Oncology reports (2016-11-24)
Ruidong Li, Xiaofei Zhang, Xiaoying Tian, Conghuan Shen, Quanbao Zhang, Yihong Zhang, Zhengxin Wang, Feifei Wang, Yifeng Tao
ZUSAMMENFASSUNG

Cellular senescence, an irreversible growth arrest of cells, is involved in protection against cancer. Triptolide (TPL) plays an important role in immunosuppressive, anti-fertility, anti-cystogenesis and anticancer activities. However, effect and mechanism of TPL on cellular senescence-associated antitumor is rarely reported. Herein HepG2 cells were used to explore the effect of TPL on tumor growth and cellular senescence. We showed that TPL inhibited tumor cell proliferation and growth in vitro and in vivo, accelerated cellular senescence and arrested cells at G0/G1 phase. We further demonstrated that TPL accelerated HepG2 cell senescence by regulating the AKT pathway. In addition, TPL could also enhance cellular senescence and inhibit tumor growth by negatively regulating human telomerase reverse transcriptase (hTERT) signaling pathway. These findings reveal a regulatory mechanism of TPL on cellular senescence, indicating that TPL promotes HepG2 cell senescence through AKT pathway and hTERT pathway simultaneously. Altogether, TPL-induced senescence can be regarded as a promising strategy for anticancer therapy and drug development.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Triptolid, from Tripterygium wilfordii, ≥98% (HPLC), solid